Jones HE - Search Results

1

Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells.

Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI. Knowlden JM, et al. Among authors: jones he. Endocrinology. 2003 Mar;144(3):1032-44. doi: 10.1210/en.2002-220620. Endocrinology. 2003. PMID: 12586780

2

Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination.

Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D, Gee JM. Nicholson RI, et al. Among authors: jones he. Clin Cancer Res. 2004 Jan 1;10(1 Pt 2):346S-54S. doi: 10.1158/1078-0432.ccr-031206. Clin Cancer Res. 2004. PMID: 14734490

3

Growth factor receptor interplay and resistance in cancer.

Jones HE, Gee JM, Hutcheson IR, Knowlden JM, Barrow D, Nicholson RI. Jones HE, et al. Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S45-51. doi: 10.1677/erc.1.01275. Endocr Relat Cancer. 2006. PMID: 17259558 Review.

4

Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy.

Hutcheson IR, Knowlden JM, Jones HE, Burmi RS, McClelland RA, Barrow D, Gee JM, Nicholson RI. Hutcheson IR, et al. Among authors: jones he. Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S89-97. doi: 10.1677/erc.1.01279. Endocr Relat Cancer. 2006. PMID: 17259562 Review.

5

Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.

Knowlden JM, Jones HE, Barrow D, Gee JM, Nicholson RI, Hutcheson IR. Knowlden JM, et al. Among authors: jones he. Breast Cancer Res Treat. 2008 Sep;111(1):79-91. doi: 10.1007/s10549-007-9763-9. Epub 2007 Sep 28. Breast Cancer Res Treat. 2008. PMID: 17902048

6

Insulin-like growth factor-I receptor signaling and resistance in breast cancer.

Jones HE, Gee JM, Hutcheson IR, Nicholson RI. Jones HE, et al. Expert Rev Endocrinol Metab. 2006 Jan;1(1):33-46. doi: 10.1586/17446651.1.1.33. Expert Rev Endocrinol Metab. 2006. PMID: 30743767

7

New EGF-R selective tyrosine kinase inhibitor reveals variable growth responses in prostate carcinoma cell lines PC-3 and DU-145.

Jones HE, Dutkowski CM, Barrow D, Harper ME, Wakeling AE, Nicholson RI. Jones HE, et al. Int J Cancer. 1997 Jun 11;71(6):1010-8. doi: 10.1002/(sici)1097-0215(19970611)71:6<1010::aid-ijc17>3.0.co;2-h. Int J Cancer. 1997. PMID: 9185705

8

Effect of an EGF-R selective tyrosine kinase inhibitor and an anti-androgen on LNCaP cells: identification of divergent growth regulatory pathways.

Jones HE, Barrow D, Dutkowski CM, Goddard L, Smith C, Harper ME, Nicholson RI. Jones HE, et al. Prostate. 2001 Sep 15;49(1):38-47. doi: 10.1002/pros.1116. Prostate. 2001. PMID: 11550209

9

Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer.

Nicholson RI, Hutcheson IR, Harper ME, Knowlden JM, Barrow D, McClelland RA, Jones HE, Wakeling AE, Gee JM. Nicholson RI, et al. Among authors: jones he. Endocr Relat Cancer. 2001 Sep;8(3):175-82. doi: 10.1677/erc.0.0080175. Endocr Relat Cancer. 2001. PMID: 11566608 Review.

10

Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer.

Nicholson RI, Hutcheson IR, Harper ME, Knowlden JM, Barrow D, McClelland RA, Jones HE, Wakeling AE, Gee JM. Nicholson RI, et al. Among authors: jones he. Ann N Y Acad Sci. 2002 Jun;963:104-15. doi: 10.1111/j.1749-6632.2002.tb04101.x. Ann N Y Acad Sci. 2002. PMID: 12095935

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

740 results

Search Page

Filters